dc.contributor.author |
White, Douglas |
en |
dc.contributor.author |
Lao, C |
en |
dc.contributor.author |
Williams, M |
en |
dc.contributor.author |
Lawrenson, R |
en |
dc.contributor.author |
Dalbeth, Nicola |
en |
dc.date.accessioned |
2020-01-23T02:00:45Z |
en |
dc.date.issued |
2019-11-29 |
en |
dc.identifier.citation |
New Zealand Medical Journal 132(1506):10-19 29 Nov 2019 |
en |
dc.identifier.issn |
0028-8446 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/49693 |
en |
dc.description.abstract |
Aim To evaluate costs associated with a diagnosis of spondyloarthritis (SpA) in an Aotearoa/New Zealand cohort. Method Patients with SpA attending specialist SpA clinics in Auckland and Hamilton completed a series of questionnaires on costs associated with ankylosing spondylitis, disease parameters (BASDAI), work productivity (WPAI, WLQ) and quality of life measures (EQ-5D, ASAS-HI). Results Eighty-one patients (median age 43 years) completed the study. All fulfilled the ASAS criteria for axial spondyloarthritis and 44 (58%) fulfilled the Modified New York Criteria for ankylosing spondylitis. The mean (SD) score on the EQ-VAS was 69mm (24.1). More than half reported difficulties with usual activities and more than 80% had moderate pain or discomfort despite current treatment. Sixty-six (82%) were in the workforce, and the mean work productivity loss was 4.8%. The mean (SD) annual cost was NZ$15,677 (NZ$11,269) with NZ$12,189 direct cost and NZ$3,488 productivity loss. The largest cost driver was use of biologic medications, which were used by 48% patients. Conclusion This study has quantified the direct and indirect costs of spondyloarthritis (SpA) in Aotearoa/New Zealand, and demonstrates meaningful reduction in quality of life and work productivity in patients with SpA. The major driver of direct costs in SpA are biologic medications. |
en |
dc.language |
English |
en |
dc.publisher |
New Zealand Medical Association |
en |
dc.relation.ispartofseries |
New Zealand Medical Journal |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.rights.uri |
https://www.nzma.org.nz/journal/contribute/articles |
en |
dc.subject |
Science & Technology |
en |
dc.subject |
Life Sciences & Biomedicine |
en |
dc.subject |
Medicine, General & Internal |
en |
dc.subject |
General & Internal Medicine |
en |
dc.subject |
HEALTH-CARE COSTS |
en |
dc.subject |
QUALITY-OF-LIFE |
en |
dc.subject |
RHEUMATOID-ARTHRITIS |
en |
dc.subject |
PSORIATIC-ARTHRITIS |
en |
dc.subject |
PRODUCTIVITY |
en |
dc.subject |
ILLNESS |
en |
dc.subject |
INDEX |
en |
dc.title |
The costs associated with ankylosing spondylitis/axial spondyloarthritis in Aotearoa/New Zealand |
en |
dc.type |
Journal Article |
en |
pubs.issue |
1506 |
en |
pubs.begin-page |
10 |
en |
pubs.volume |
132 |
en |
dc.rights.holder |
Copyright: NZMA |
en |
pubs.author-url |
https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2019/vol-132-no-1506-29-november-2019/8054 |
en |
pubs.end-page |
19 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
789050 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Medicine Department |
en |
dc.identifier.eissn |
1175-8716 |
en |
pubs.record-created-at-source-date |
2020-01-23 |
en |